Clinical trial · Observational
The Prognostic Role of Fibrinogen to Albumin Ratio in Acute Leukemia Patients
NCT06668948CI-TRIAL-00082166not yet recruitingClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
The study aim to investigate whether levels of acute phase reactants at diagnosis and after 6 months of follow-up correlate with survival and response to treatment in newly diagnosed acute leukemia.Ultimately, we will evaluate the fibrinogen/albumin ratio, a simple score based on acute phase protein levels, whether it can provide relevant prognostic information in acute leukemia patients at diagnosis and after 6 months of follow-up.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Patients with Acute Leukemia | Acute Leukemia | ONTOLOGY_EXACT | 0.85 |
Interventions
Interventions (0)
Data not yet available
No intervention recorded.
Design
Arms and outcomes
Arms (1)
- label
- patients with acute leukemia
Primary outcomes (1)
- measure
- The prognostic role of fibrinogen to albumin ratio in acute leukemia patients
- timeFrame
- 2025
Eligibility
Eligibility (as posted)
- Sex
- All
Show eligibility criteria text
Inclusion Criteria: * Inclusion criteria: 1. Newly diagnosed patients with acuteleukemia 2. Not received any treatment Exclusion Criteria: * Exclusion criteria: 1. Patients with chronic inflammatory diseases (e.g., rheumatoid arthritisinflammatory bowel disease) or acute infections that may affect acute phase protein levels. 2. Patients under chemotherapy or radiotherapy
References
Publications (0)
Data not yet available
No reference posted for this study.